The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
As of Jan. 1, 2020, JITC transitioned to a new publishing relationship with BMJ. The journal’s new publication home, complete with JITC’s fully-searchable article archive, is jitc.bmj.com. Read more about this exciting change in the editorial announcement from JITC’s Editor-in-Chief Dr. Pedro J. Romero.
As of Oct. 10, 2019, JITC has transitioned to ScholarOne for all new manuscripts. If you have any questions regarding submission to the new peer review system, or require assistance submitting your manuscript, please contact the Editorial Assistant (firstname.lastname@example.org).
JITC is launching two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy", and submit today!
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 8.728 in 2019. JITC’s impact factor places JITC in the top 3 percent of all fully open access oncology journals and ranks it in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2018 citations accumulated for JITC manuscripts published in 2016 and 2017. Other journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2020.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit from ICIs is a major research focus for the oncology community. Thus far, predictive biomarker research has focused on tumor signatures such as microsatellite instability, programmed death-ligand 1 (PD-L1) expression and tumor mutational burden; clinical biomarkers have been far less studied. One potential clinical biomarker for ICI response in patients is immune-related adverse event (IRAE) onset.
The PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with IFN-g signaling. To characterize other factors regulating PD-L1 expression on tumor and/or immune cells, we investigated TME-resident cytokines and the role of transcription factors in constitutive and cytokine-induced PD-L1 expression.
April 17, 2020 - Philadelphia, PA
The 2nd Annual Head and Neck Cancer Symposium: A Multidisciplinary Approach offers participants an active learning format featuring didactic lectures, panel discussions that will include audience interaction, ...
March 5-6, 2020 Philadelphia, PA - Center City Campus of Thomas Jefferson University
This two-day course is designed for healthcare professionals whose practices focus on the screening, diagnosis, management, and treatment of lung cancer using ...
Dear All, I'll be attending SITC 2019 on November 7-8 and would like to network with anyone interested in or studying these topics. I'm new to the field of IO therapy and would appreciate any help making connections. Thanks, Rick ------------------------------ ...
Princeton Center for Theoretical Science presents the 2019 Distinguished Visiting Lecturer
Laboratoire de Physique Théorique Ecole Normale Supérieure Public Lecture : "The Evolution Within Us: Statistics of Immunity" ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com